![Benita Prud’homme](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Actieve functies van Benita Prud’homme
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Lucida Medical Ltd.
![]() Lucida Medical Ltd. Medical SpecialtiesHealth Technology Lucida Medical Ltd. is a start-up based in Cambridge, UK that develops AI-based technology to assist clinicians in finding cancer more accurately, diagnosing and treating it more effectively, and saving time. The company was founded in 2019 by Dr. Antony Rix, an expert in medical devices, machine learning, and AI, and Prof. Evis Sala, who was a professor of oncological imaging at the University of Cambridge & Addenbrookes Hospital at the time. Lucida Medical's first product, Prostate Intelligence™ (PI™), is intended for use to assist in the diagnosis of prostate cancer and has completed regulatory approvals. The British company enables healthcare professionals to find cancer quickly and efficiently with artificial intelligence (AI) and magnetic resonance imaging (MRI). Antony William Rix has been the CEO since incorporation. | Operationeel Directeur | - | - |
Loopbaan van Benita Prud’homme
Statistieken
Internationaal
Verenigd Koninkrijk | 2 |
Operationeel
Chief Operating Officer | 1 |
Sectoraal
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Lucida Medical Ltd.
![]() Lucida Medical Ltd. Medical SpecialtiesHealth Technology Lucida Medical Ltd. is a start-up based in Cambridge, UK that develops AI-based technology to assist clinicians in finding cancer more accurately, diagnosing and treating it more effectively, and saving time. The company was founded in 2019 by Dr. Antony Rix, an expert in medical devices, machine learning, and AI, and Prof. Evis Sala, who was a professor of oncological imaging at the University of Cambridge & Addenbrookes Hospital at the time. Lucida Medical's first product, Prostate Intelligence™ (PI™), is intended for use to assist in the diagnosis of prostate cancer and has completed regulatory approvals. The British company enables healthcare professionals to find cancer quickly and efficiently with artificial intelligence (AI) and magnetic resonance imaging (MRI). Antony William Rix has been the CEO since incorporation. | Health Technology |
- Beurs
- Insiders
- Benita Prud’homme
- Ervaring